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OBJECTIVE: The objective was to investigate the plasma levels and to compare the pharmacokinetics of cefuroxime during and
after surgery in adult patients with elective indication for coronary artery bypass grafting.
METHODS: Seventeen patients received three 1.5-g bolus IV doses of cefuroxime, one every 12 hrs. Serial blood samples (3 mL)
were collected 1, 3, 6, 9, and 12 hrs after the first dose (given during the intervention) and after the second and third doses (postsurgery).
Blood samples were centrifuged and stored frozen until being assayed. For assessment of the cefuroxime plasma levels by liquid
chromatography, only 200 µL of plasma were required. Determination of cefuroxime plasma levels was followed by a pharmacokinetic
(PK)-modeling using PK Solutions 2.0 software.
RESULTS: The kinetic parameters obtained remained unchanged after the first, second, and the third dose as follows: elimination half-
life: 1.8 h, 1.9 h, and 1.8 h; clearance: 1.4, 1.5, and 1.5 mL/min/kg, respectively. Additionally, the apparent volume of distribution did not
change during and after the intervention: 0.19, 0.25, and 0.22 L/kg, after the first, second, and the third dose, respectively. Since the drug
has a low volume of distribution, plasma levels obtained after a 1.5-g IV bolus injection of cefuroxime decreased rapidly due to the high
plasma clearance, with a consequent short half-life.
CONCLUSIONS: The kinetic disposition of cefuroxime remains unaltered in patients undergoing coronary artery bypass grafting;
to reduce the fluctuation in plasma concentrations so that the antibiotic prophylaxis in the peri-operative period is guaranteed, the
dose regimen should be reviewed.
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INTRODUCTION
Myocardial revascularization surgery is a common pro-
cedure, but despite clinical and surgical advances, nosoco-
mial infection continues to be a reality for hospitals world-
wide, endangering patients’ rehabilitation. Prophylactic an-
timicrobial regimens have been used since the 1960s in such
patients, aiming to reduce the incidence of infection, time
of hospitalization, and consequently, treatment costs.1,2
The nature of the antibiotics and the dosing regimens (dose
and frequency of administration) vary according to current hos-
pital protocols, type of surgery, and surgical procedures.1–4
Due to the low toxicity and good tissue penetration, sec-
ond generation cephalosporin is the antibiotic of choice for
the prophylaxis of postsurgical infections in many surger-
ies, including cardiac surgery. Cefuroxime has a good cost-
benefit relationship, with a reasonable price compared with
other cephalosporins, as well as a favorable spectrum of
action, preventing the growth of most bacteria found in
postoperative site infections; therefore, it is highly recom-
mended for antibiotic prophylaxis.1,2
In the present study, the pharmacokinetics of
cefuroxime in the peri-operative period in patients under-
going coronary artery bypass grafting (CABG) as well the
plasma concentrations after a dosing regimen applied for
antimicrobial prophylaxis were investigated.
MATERIALS AND METHODS
Patients and clinical procedures
The study protocol was approved by the hospital’s Eth-
ics Committee, and a signed written informed consent was
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obtained from all the patients. Seventeen adult patients, 11
men and 6 women scheduled for CABG in the Instituto do
Coração, Hospital das Clínicas, Faculty of Medicine, Univ.
São Paulo were enrolled in the study. Inclusion criteria were
as follows: a) left ventricular ejection fraction > 50% and
normal right ventricular function, as assessed by preoperative
transthoracic echocardiography within a week before surgery,
b) hepatic and renal functions monitored during all investi-
gations were in the reference range for serum AST, ALT, total
bilirubin, and creatinine; additionally, renal function was as-
sessed by creatinine clearance estimated based on serum cre-
atinine for all patients investigated. Patients with diabetes
mellitus, chronic obstructive pulmonary disease, or periph-
eral artery vascular disease were excluded.
Characteristics of patients and duration of surgery were
as follows (expressed as mean ± SD): age: 50.7 ± 9.1 years,
weight: 71.2 ± 8.7 kg, height: 166.9 ± 8.3 cm, and BMI:
25.7 ± 2.7 kg/m2. The duration of surgery was 4.0 ± 1.1 h.
Any occurrence of surgical site infection in the patients in-
cluded in the protocol was verified. Additionally, no patient
presented significant bleeding during the surgery, and no
blood transfusion during or after the surgery was reported.
Prophylactic cefuroxime was given during the peri-op-
erative period, and 3 1.5 g doses were administered at 12 hr
intervals, as follows: preoperative (first dose immediately
before the beginning of the surgery), immediate (12 hr) and
late postoperative period (24hr). Serial 3-mL blood samples
were collected 1, 3, 6, 9, and 12 hours after each dose.
Blood samples were centrifuged and stored frozen un-
til being assayed by high-pressure liquid chromatography
(HPLC) as described previously for cefuroxime in plasma.5
Only 200 µL of plasma was required for the assay because
of the addition of 0.0025 mg/assay vancomycin (internal stand-
ard 100 mg/L) and 0.4 mL of acetonitrile for the precipitation
of plasma proteins; the mixture was vortexed, followed by cen-
trifugation at 10000 g for 20 min, and residue was discarded.
Volumes of 0.2 mL of the supernatant were transferred to coni-
cal tubes and evaporated under a stream of nitrogen; the resi-
due was dissolved in a mixture of water and acetonitrile (6:4
v/v) and injected automatically into the HPLC device. A
NovaPak C18, 150 x 4.5 mm, 5-micron column containing C18
inserts and a mobile phase containing 0.375 M acetate buffer
and acetonitrile (94:6, v/v) at a flow rate of 1 mL/min was used.
The internal standard (vancomycin) and cefuroxime were eluted
from the column at 4.0 min and 12.5 min, respectively, and
peaks were monitored by a UV detector at a 280 nm wave-
length. The method had the following characteristics: 0.2-200
mg/L (linearity; r2 0.9963), 0.2 mg/L (limit of quantification),
0.1 mg/L (limit of detection), 3.2% and 4.2% intra- and inter-
day precision, respectively, and the systematic error showing
intra- and inter-day accuracy of 98.2 and 96.9%, respectively.
A good recovery (99.2%) and stability higher than 24 hours at
room temperature were obtained for the analytical method.5
Pharmacokinetics and Statistics
Pharmacokinetic modeling was obtained by plotting
cefuroxime plasma levels (logarithmic transformation) against
time. The software, PK Solutions version 2.0 (Summit Research
Services, Montrose, Colorado, USA), was applied to the data
obtained using a 1-compartment open model after intravenous
dose administration. Kinetic parameters, including elimination
rate constant (Kel), biological half-life (t½β), plasma clearance
rate (CLT), and apparent volume of distribution (Vd), were de-
termined after the first, second, and third doses given to each
patient investigated (during and after surgery).
The theoretical maximum cefuroxime plasma concen-
tration (0 hour) was obtained by back extrapolation of the
plasma decay curve, ie, the logarithmic transformation of
cefuroxime plasma concentration (Y axis) vs time (X axis).
Data estimated or parameters obtained after PK-modeling
were statistically analyzed by the nonparametric Mann-Whitney
test for paired data via the comparison of cefuroxime adminis-
tered at the pre- versus postoperative periods for all patients,
using GraphPad Instat software, version 2.01 (San Diego, USA),
with a P value < .05 being considered significant.
RESULTS
The plasma drug decay curve after cefuroxime admin-
istration (first, second, and third doses) during and after sur-
gery are shown in Figure 1, with values expressed as mean
+/- SEM. Plasma concentration at 0 was obtained by back
extrapolation of the plasma curve decay (logarithmic trans-
formation of plasma concentration).
The kinetic parameters were expressed in terms of median
and the variation range of the 95% confidence interval, since a
nonparametric test was applied in the statistics. The pharma-
cokinetics of cefuroxime for each patient after the administra-
tion of the second and third doses was compared to the that
after the first dose, which was given preoperatively (Table1).
Figure 1 - Plasma drug decay for cefuroxime (1.5 g, IV) given to surgical
patients undergoing coronary artery bypass grafting; C (mg/L, mean/SEM
vs T (hrs). ---- Equivalent to 4 mg/L (minimal inhibitory concentration: MIC).
—— Equivalent to 16 mg/L (4 x MIC)
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DISCUSSION
Several invasive procedures are performed during cardiac
surgery that expose patients to opportunistic bacteria. Asep-
tic procedures, the training of the surgical team, and the cor-
rect antibiotic prophylaxis are important factors that contrib-
ute to the reduction of the incidence of postsurgical infections.
Despite the efforts of infection control committees, these com-
plications involving nosocomial infections have been reported
in the hospitals in this country and worldwide. Data reported
previously show an incidence of 5% to 10% of postsurgical
infections in patients undergoing to cardiac surgery.6–8
As reported by the Infection Control Committee of
Instituto do Coração (University of Medical School) the
rates of postsurgical infections including superficial or deep
infections, mediastinitis, thoracic osteomyelitis, and limb
wound infections were lower than 10% over the past 5
years. However, none of the patients evaluated in this study
protocol presented any postsurgical infection.
Since the 1960s, the prophylactic administration of anti-
microbial agents has been proposed to reduce the incidence
of these infections, and today it is an important routine pro-
cedure for patients undergoing surgeries such as cardiovascu-
lar interventions. Antibiotic prophylaxis substantially reduces
the incidence of infections, the time of hospitalization, and
consequently the costs of treatment, as reported previously.4,10
A large number of different dose regimens with
cefuroxime have been described for surgical prophylaxis,
including a single 3-g bolus IV dose before surgery, or the
administration of several doses (3 to 4.5 g), with regimens
of, for instance, 1.5-g IV bolus every 8 or every 12 hours,
or a continuous infusion of 125 mg/hr for 24 hours.4,6–10
In this study, the antimicrobial agent was given as fol-
lows: 1.5 g starting preoperatively (first dose, given imme-
diately before the beginning of surgery), and 1.5 g in the
immediate and late postoperative period. In general, a mini-
mal inhibitory concentration (MIC) for cefuroxime is equiva-
lent to 4 mg/L. However, a trough level of 4-fold the mini-
mal inhibitory concentration (4 x 4 mg/L = 16 mg/L) is rec-
ommended to improve prophylaxis, since the drug has a large
therapeutic index, and adverse effects have not been reported
as a consequence of high plasma concentrations.8,9,11,12
In the present study, plasma concentrations of cefuroxime
were shown to reduce rapidly as a consequence of its short
half-life, Figure 1. Data obtained after drug administration
showed cefuroxime plasma concentrations below 16 mg/L
after the sixth hour (4 times the minimum inhibiting con-
centration (MIC) of 4 mg/L), and below the MIC after the
9th hour, at all dosing times, both pre- and postsurgical.
No accumulation was registered at the 12th hour (time
dose interval), and consequently a single dose administra-
tion must be considered, since no residue was found after
several doses of 1.5 g, IV. Based on these considerations,
the washout of cefuroxime was completed every 12 hours,
as illustrated in Figure 1.
The kinetic disposition of cefuroxime was investigated
based on plasma curve decay applying a 1-compartment open
model using a quite simple, sensitive, selective, and low-cost
micromethod, requiring only 200µL of plasma per sample.5
No significant difference in comparisons between the
first, second, and third doses were observed in the kinetic
parameters, elimination rate constant, biological half-life,
plasma clearance, and apparent volume of distribution, as
shown on Table 1. These findings were very close to those
reported for healthy volunteers,3 and they suggest that the
kinetic disposition of cefuroxime is unaltered by surgery
in patients with preserved renal function.
Additionally, cefuroxime plasma concentrations reduced
rapidly after the IV bolus for the surgical patients investi-
gated (Figure 1); data obtained were close to the results
reported previously in healthy volunteers.3
It is also known that the bactericidal action of the anti-
microbial agent is not directly related to maximum plasma
concentration reached, but to the period of time during
which plasma levels are maintained at levels above 4 to 8
times the MIC.8–11
According to the exponential curve decay, shown in Figure
1, the maximum plasma concentration reached was approxi-
mately 100 mg/L and fell rapidly to below 16 mg/L at the 6th
hour and below 4 mg/L at the 9th hour after drug administra-
Table 1 - Kinetics of cefuroxime in patients submitted to coronary artery bypass grafting, n=17
Cefuroxime Median
(95% CI)
Dose 1.5 g IV, bolus Kel(h-1) Half-life(hour) CLTmL/min/kg VdL/kg
Reference 3 0.40 1.7 1.4 0.20
1st dose 0.38(0.36 - 0.42) 1.8(1.7 - 2.0) 1.4(1.1 - 1.6) 0.19(0.15 - 0.26)
2nd dose 0.36(0.34 - 0.46) 1.9(1.5 - 2.0) 1.5(1.0 - 1.9) 0.25(0.16 - 0.30)
P .8125 .8125 .6875 .1094
3rd dose 0.39(0.32 - 0.55) 1.8(1.3 - 2.1) 1.5(1.2 - 2.4) 0.22(0.19 - 0.37)
P .8125 .8125 .1190 .2188
P: 2nd dose or 3rd dose vs the 1st dose; Statistically significant when P < 0.05. Mann Whitney test; CI = confidence interval; Kel = elimination rate constant,
CLT = plasma clearance rate; Vd = apparent volume distribution
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tion. Considering the postoperative period (1st and 2nd day), data
obtained suggest that the washout of cefuroxime was completed
12 hours after each of the second and the third doses.
A linear pharmacokinetics for cefuroxime was found at
the dose regimen applied, since kinetic parameters for dis-
tribution and elimination of drug remained unchanged dur-
ing and after surgery. The kinetic disposition of cefuroxime
remained unaltered in patients undergoing coronary artery
bypass grafting. To reduce the fluctuation in plasma lev-
els, guaranteeing antibiotic prophylaxis in the peri-opera-
tive period, the dose regimen should be reviewed.
CONCLUSION
The results obtained allow us to suggest that the kinetic dis-
position of cefuroxime is unaltered by the surgery in patients
undergoing CABG at the dose regimen of 1.5 g every 12 hours.
RESUMO
Nascimento JWL, Carmona MJC, Strabelli TMV, Auler Jr
JOC, Santos SRCJ. Farmacocinética da Cefuroxima na
antibioticoprofilaxia de cirurgia cardíaca. Clinics.
2007;62(3):257-60.
OBJETIVO: Investigar os níveis plasmáticos e comparar
a farmacocinética da cefuroxima durante e após cirurgia
de revascularização do miocárdio.
MÉTODOS: Dezessete pacientes receberam três doses
intravenosas de 1,5 g de cefuroxima, a cada 12 horas. Foram
coletadas amostras de sangue nos tempos de 1, 3, 6, 9 e 12
horas após a primeira dose (durante a cirurgia) e após a
segunda e terceira dose (administradas após a cirurgia). As
amostras de sangue foram centrifugadas e armazenadas
congeladas até o momento da análise. Os níveis plasmáticos
da cefuroxima foram determinados através de cromatografia
líquida, utilizando-se apenas 200 mL de plasma. A
determinação da farmacocinética da cefuroxima foi realizada
utilizando o software PK-solutions 2.0.
RESULTADOS: Todos os parâmetros cinéticos obtidos
permaneceram inalterados após a adminstração da 1a, 2a e
3a doses: meia vida de eliminação 1,8h, 1,9h and 1,8h,
depuração  1,4, 1,5 and 1,5 mL/min/kg  respectivamente.
Adicionalmente, o volume aparente de distribuição, não se
alterou durante ou após a intervenção: 0,19, 0,25 and 0,22
L/kg, após 1a, 2a e 3a dose, respectivamente. Os níveis
plasmáticos obtidos após administração da cefuroxima
reduziram rapidamente devido à alta depuração plasmática
com conseqüente curta meia-vida plasmática, atingindo
valores abaixo da concentração inibitória mínima a partir
da 9a hora da administração.
CONCLUSÕES: A disposição cinética da cefuroxima
permanece inalterada em pacientes submetidos à cirurgia
de revascularização do miocárdio, e com vistas à redução
da flutuação no período perioperatório, o regime de dose
para a antibioticoprofilaxia poderia ser revisto.
UNITERMOS: Cefuroxima, Farmacocinética, Antibiótico,
Cromatografia, Cirurgia cardíaca
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